Microsomal prostaglandin e synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity

British Journal of Pharmacology

Volumn 159, Issue 5, 2010, Pages 1174-1186

  Ikeda Matsuo, Y ^a   Hirayama, Y ^a   Ota, A ^a   Uematsu, S ^b   Akira, S ^b   Sasaki, Y ^a  

^a KITASATO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Excitotoxicity; Glutamate; Inflammation; Ischaemia; Prostaglandin E synthase; Prostaglandin E 2; Stroke

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUTAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E SYNTHASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXCITOTOXICITY; FEMALE; HIPPOCAMPUS; IN VIVO STUDY; ISCHEMIA; KNOCKOUT MOUSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; WILD TYPE;

ANIMALS; BRAIN ISCHEMIA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; GLUTAMIC ACID; HIPPOCAMPUS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSOMES; NEURONS; RATS; REPERFUSION INJURY; STROKE;

EID: 77949391334     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00595.x     Document Type: Article

References (73)

1. 4 receptor agonist protects against acute neurotoxicity. Brain Res 1066: 71-77.
2. 1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 89: 265-270.
3. Ahmad M, Zhang Y, Liu H, Rose ME, Graham SH (2009). Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain Res 1279: 168-173.
4. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
5. Armstead WM, Mirro R, Busija DW, Leffler CW (1988). post-ischaemic generation of superoxide anion by newborn pig brain. Am J Physiol 255: H401-H403.
6. Bading H, Segal MM, Sucher NJ, Dudek H, Lipton SA, Greenberg ME (1995). N-methyl-D-aspartate receptors are critical for mediating the effects of glutamate on intracellular calcium concentration and immediate early gene expression in cultured hippocampal neurons. Neuroscience 64: 653-664.
7. Barakat W, Herrmann O, Baumann B, Schwaninger M (2009). NF-kappaB induces PGE2-synthesizing enzymes in neurons. Naunyn Schmiedebergs Arch Pharmacol 380: 153-160.
8. Barone FC, Feuerstein GZ (1999). Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 19: 819-834.
9. Butcher SP, Bullock R, Graham DI, McCulloch J (1990). Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 21: 1727-1733.
10. Candelario-Jalil E, González-Falcón A, García- Cabrera M, Alvarez D, Al-Dalain S, Martínez G et al. (2003). Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 86: 545-555.
11. Candelario-Jalil E, González-Falcón A, García- Cabrera M, León OS, Fiebich BL (2004). Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res 1007: 98-108.
12. Chan PH (2001). Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21: 2-14.
13. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926-13931.
14. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y et al. (2003). Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvantinduced arthritis model. J Immunol 170: 4738-4744.
15. Cui Y, Takamatsu H, Kakiuchi T, Ohba H, Kataoka Y, Yokoyama C et al. (2006). Neuroprotection by a central nervous system-type prostacyclin receptor ligand demonstrated in monkeys subjected to middle cerebral artery occlusion and reperfusion: a positron emission tomography study. Stroke 37: 2830-2836.
16. Dávalos A, Shuaib A, Wahlgren NG (2000). Neurotransmitters and pathophysiology of stroke: evidence for the release of glutamate and other transmitters/mediators in animals and humans. J Stroke Cerebrovasc Dis 9: 2-8.
17. Dirnagl U, Iadecola C, Moskowitz MA (1999). Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22: 391-397.
18. Domoki F, Perciaccante JV, Puskar M, Bari F, Busija DW (2001). Cyclooxygenase-2 inhibitor NS398 preserves neuronal function after hypoxia/ischemia in piglets. Neuroreport 12: 4065-4068.
19. Fan W, Cooper NG (2009). Glutamate-induced NFkappaB activation in the retina. Invest Ophthalmol Vis Sci 50: 917-925.
20. Govoni S, Masoero E, Favalli L, Rozza A, Scelsi R, Viappiani S et al. (2001). The Cycloxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci Lett 303: 91-94.
21. Hall ED, Andrus PK, Althaus JS, VonVoigtlander PF (1993). Hydroxyl radical production and lipid peroxidation parallels selective postischemic vulnerability in gerbil brain. J Neurosci Res 34: 107-112.
22. Huang FP, Wang ZQ, Wu DC, Schielke GP, Sun Y, Yang GY (2003). Early NFkappaB activation is inhibited during focal cerebral ischemia in interleukin-1beta-converting enzyme deficient mice. J Neurosci Res 73: 698-707.
23. Iadecola C, Forster C, Nogawa S, Clark HB, Ross ME (1999). Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol 98: 9-14.
24. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E et al. (2001). Reduced susceptibility to ischemic brain injury and N-methyl-D- aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98: 1294-1299.
25. Iijima T, Sawa H, Shiokawa Y, Saito I, Ishii H, Nakamura Z et al. (1996). Thromboxane synthetase inhibitor ameliorates delayed neuronal death in the CA1 subfield of the hippocampus after transient global ischemia in gerbils. J Neurosurg Anesthesiol 8: 237-242.
26. 2+ increase in Neuro-2A cells and rat astrocytes following stimulation of bradykinin B2 receptor. Jpn J Pharmacol 84: 140-145.
27. Ikeda-Matsuo Y, Ikegaya Y, Matsuki N, Uematsu S, Akira S, Sasaki Y (2005). Microglia-specific expression of microsomal prostaglandin E synthase-1 contributes to lipopolysaccharide-induced prostaglandin E2 production. J Neurochem 94: 1546-1558.
28. Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y (2006). Microsomal prostaglndin E synthase-1 is a critical factor of strokereperfusion injury. Proc Natl Acad Sci USA 103: 11790-11795.
29. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999). Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96: 7220-7225.
30. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF (1997). Cyclooxygenases and the central nervous system. Prostaglandins 54: 601-624.
31. 1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12: 225-229.
32. Kempski O, Shohami E, von Lubitz D, Hallenbeck JM, Feuerstein G (1987). post-ischaemic production of eicosanoids in gerbil brain. Stroke 18: 111-119.
33. Koeberle A, Siemoneit U, Northoff H, Hofmann B, Schneider G, Werz O (2009). MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation. Eur J Pharmacol 608: 84-90.
34. Kojima F, Naraba H, Sasaki Y, Beppu M, Aoki H, Kawai S (2003). Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 48: 2819-2828.
35. Kontos HA, Wei EP, Povlishock JT, Dietrich WD, Magiera CJ, Ellis EF (1980). Cerebral arteriolar damage by arachidonic acid and prostaglandin G2. Science 209: 1242-1245.
36. Kunz A, Anrather J, Zhou P, Orio M, Iadecola C (2007). Cyclooxygenase-2 does not contribute to post-ischaemic production of reactive oxygen species. J Cereb Blood Flow Metab 27: 545-551.
37. Lee JM, Zipfel GJ, Choi DW (1999). The changing landscape of ischaemic brain injury mechanisms. Nature 399: A7-A14.
38. Lu A, Tang Y, Ran R, Clark JF, Aronow BJ, Sharp FR (2003). Genomics of the periinfarction cortex after focal cerebral ischemia. J Cereb Blood Flow Metab 23: 786-810.
39. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999). Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277.
40. McAdam BF, Byrne D, Morrow JD, Oates JA (2005). Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 112: 1024-1029.
41. McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q et al. (2004). Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24: 257-268.
42. 2 receptor antagonist, S-1452, on post-ischaemic brain injury in rats. Stroke 24: 2059-2064.
43. Miettinen S, Fusco FR, Yrjänheikki J, Keinänen R, Hirvonen T, Roivainen R et al. (1997). Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci U S A 94: 6500-6505.
44. Minuz P (2008). Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event?. J Am Coll Cardiol 52: 1637-1639.
45. Murakami M, Nakatani Y, Tanioka T, Kudo I (2002). Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 68-69: 383-399.
46. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F et al. (2000). Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275: 32783-32792.
47. Naraba H, Yokoyama C, Tago N, Murakami M, Kudo I, Fueki M et al. (2002). Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J Biol Chem 277: 28601-28608.
48. Nelson CW,Wei EP, Povlishock JT, Kontos HA, Moskowitz MA (1992). Oxygen radicals in cerebral ischemia. Am J Physiol 263: H1356-H1362.
49. Nogawa S, Zhang F, Ross ME, Iadecola C (1997). Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17: 2746-2755.
50. de Oliveira AC, Candelario-Jalil E, Bhatia HS, Lieb K, Hüll M, Fiebich BL (2008). Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia 56: 844-855.
51. Ouellet M, Percival MD (1995). Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 306: 247-251.
52. Quan N, Whiteside M, Herkenham M (1998). Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. Brain Res 802: 189-197.
53. Rose JW, Hill KE, Watt HE, Carlson NG (2004). Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J Neuroimmunol 149: 40-49.
54. Saleem S, Zhuang H, de Brum-Fernandes AJ, Maruyama T, Narumiya S, Doré S (2007). PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci 26: 73-78.
55. 3 receptor-deficient mice after cerebral ischemia. J Neuroimmunol 208: 87-93.
56. Samuelsson B, Morgenstern R, Jakobsson PJ (2007). Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224.
57. Sasaki T, Kitagawa K, Yamagata K, Takemiya T, Tanaka S, Omura-Matsuoka E et al. (2004). Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J Cereb Blood Flow Metab 24: 107-113.
58. Sugimoto K, Iadecola C (2003). Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res 960: 273-276.
59. Sunose Y, Takeyoshi I, Ohwada S, Tsutsumi H, Iwazaki S, Kawata K et al. (2001). The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model. J Am Coll Surg 192: 54-62.
60. Takadera T, Shiraishi Y, Ohyashiki T (2004). Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem Int 45: 713-719.
61. Taniguchi H, Mohri I, Okabe-Arahori H, Aritake K, Wada K, Kanekiyo T et al. (2007). Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. J Neurosci 27: 4303-4312.
62. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I (2000). Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275: 32775-32782.
63. 49 cells. Inhibition by NS-398 and leukotriene C4. Eur J Biochem 267: 6428-6434.
64. Thornhill J, Asselin J (1999). The effect of head cooling on the physiological responses and resultant neural damage to global hemispheric hypoxic ischemia in prostaglandin E2 treated rats. Brain Res. 825: 36-45.
65. Tomimoto H, Akiguchi I, Wakita H, Lin JX, Budka H (2000). Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta Neuropathol 99: 26-30.
66. Torres L, Anderson C, Marro P, Mishra OP, Delivoria-Papadopoulos M (2004). Cyclooxygenase-mediated generation of free radicals during hypoxia in the cerebral cortex of newborn piglets. Neurochem Res 29: 1825-1830.
67. Traystman RJ, Kirsch JR, Koehler RC (1991). Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 71: 1185-1195.
68. Tyurin VA, Tyurina YY, Borisenko GG, Sokolova TV, Ritov VB, Quinn PJ et al. (2000). Oxidative stress following traumatic brain injury in rats: quantitation of biomarkers and detection of free radical intermediates. J Neurochem 75: 2178-2189.
69. Uematsu S, Matsumoto M, Takeda K, Akira S (2002). Lipopolysaccharide- dependent prostaglandin E2 production is regulated by the glutathione-dependent prostaglandin E2 synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 168: 5811-5816.
70. Vazquez-Tello A, Fan L, Hou X, Joyal JS, Mancini JA, Quiniou C et al. (2004). Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain. Am J Physiol Regul Integr Comp Physiol 287: R1155-R1163.
71. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 96: 7563-7568.
72. Wei G, Kibler KK, Koehler RC, Maruyama T, Narumiya S, Doré S (2008). Prostacyclin receptor deletion aggravates hippocampal neuronal loss after bilateral common carotid artery occlusion in mouse. Neuroscience 156: 1111-1117.
73. Yokota C, Kaji T, Kuge Y, Inoue H, Tamaki N, Minematsu K (2004). Temporal and topographic profiles of cyclooxygenase-2 expression during 24 h of focal brain ishemia in rats. Neurosci Lett 357: 219-222.